Early Hydroxychloroquine Administration for Rapid Severe Acute Respiratory Syndrome Coronavirus 2 Eradication

There are no proven therapeutics for Coronavirus disease 2019 (COVID-19) pneumonia outbreak. We observed and analyzed the clinical efficacy of the most used hydroxychloroquine (HCQ) for 30 days. In this study, administration of HCQ <5 days from diagnosis (odds ratio: 0.111, 95% confidence interva...

Descripción completa

Detalles Bibliográficos
Autores principales: Hong, Kyung Soo, Jang, Jong Geol, Hur, Jian, Lee, Jong Ho, Kim, Hong Nam, Lee, Wonhwa, Ahn, June Hong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Society of Infectious Diseases and Korean Society for Chemotherapy 2020
Materias:
Brief Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7533217/
https://www.ncbi.nlm.nih.gov/pubmed/32757497
http://dx.doi.org/10.3947/ic.2020.52.3.396
_version_ 1783590083080749056
author Hong, Kyung Soo
Jang, Jong Geol
Hur, Jian
Lee, Jong Ho
Kim, Hong Nam
Lee, Wonhwa
Ahn, June Hong
author_facet Hong, Kyung Soo
Jang, Jong Geol
Hur, Jian
Lee, Jong Ho
Kim, Hong Nam
Lee, Wonhwa
Ahn, June Hong
author_sort Hong, Kyung Soo
collection PubMed
description There are no proven therapeutics for Coronavirus disease 2019 (COVID-19) pneumonia outbreak. We observed and analyzed the clinical efficacy of the most used hydroxychloroquine (HCQ) for 30 days. In this study, administration of HCQ <5 days from diagnosis (odds ratio: 0.111, 95% confidence interval: 0.034 - 0.367, P = 0.001) was the only protective factor for prolonging of viral shedding in COVID-19 patients. Early administration of HCQ significantly ameliorates inflammatory cytokine secretion by eradicating COVID-19, at discharge. Our findings suggest that patients confirmed of COVID-19 infection should be administrated HCQ as soon as possible.
format Online
Article
Text
id pubmed-7533217
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher The Korean Society of Infectious Diseases and Korean Society for Chemotherapy
record_format MEDLINE/PubMed
spelling pubmed-75332172020-10-13 Early Hydroxychloroquine Administration for Rapid Severe Acute Respiratory Syndrome Coronavirus 2 Eradication Hong, Kyung Soo Jang, Jong Geol Hur, Jian Lee, Jong Ho Kim, Hong Nam Lee, Wonhwa Ahn, June Hong Infect Chemother Brief Communication There are no proven therapeutics for Coronavirus disease 2019 (COVID-19) pneumonia outbreak. We observed and analyzed the clinical efficacy of the most used hydroxychloroquine (HCQ) for 30 days. In this study, administration of HCQ <5 days from diagnosis (odds ratio: 0.111, 95% confidence interval: 0.034 - 0.367, P = 0.001) was the only protective factor for prolonging of viral shedding in COVID-19 patients. Early administration of HCQ significantly ameliorates inflammatory cytokine secretion by eradicating COVID-19, at discharge. Our findings suggest that patients confirmed of COVID-19 infection should be administrated HCQ as soon as possible. The Korean Society of Infectious Diseases and Korean Society for Chemotherapy 2020-09 2020-07-16 /pmc/articles/PMC7533217/ /pubmed/32757497 http://dx.doi.org/10.3947/ic.2020.52.3.396 Text en Copyright © 2020 by The Korean Society of Infectious Diseases, Korean Society for Antimicrobial Therapy, and The Korean Society for AIDS https://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Brief Communication
Hong, Kyung Soo
Jang, Jong Geol
Hur, Jian
Lee, Jong Ho
Kim, Hong Nam
Lee, Wonhwa
Ahn, June Hong
Early Hydroxychloroquine Administration for Rapid Severe Acute Respiratory Syndrome Coronavirus 2 Eradication
title Early Hydroxychloroquine Administration for Rapid Severe Acute Respiratory Syndrome Coronavirus 2 Eradication
title_full Early Hydroxychloroquine Administration for Rapid Severe Acute Respiratory Syndrome Coronavirus 2 Eradication
title_fullStr Early Hydroxychloroquine Administration for Rapid Severe Acute Respiratory Syndrome Coronavirus 2 Eradication
title_full_unstemmed Early Hydroxychloroquine Administration for Rapid Severe Acute Respiratory Syndrome Coronavirus 2 Eradication
title_short Early Hydroxychloroquine Administration for Rapid Severe Acute Respiratory Syndrome Coronavirus 2 Eradication
title_sort early hydroxychloroquine administration for rapid severe acute respiratory syndrome coronavirus 2 eradication
topic Brief Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7533217/
https://www.ncbi.nlm.nih.gov/pubmed/32757497
http://dx.doi.org/10.3947/ic.2020.52.3.396
work_keys_str_mv AT hongkyungsoo earlyhydroxychloroquineadministrationforrapidsevereacuterespiratorysyndromecoronavirus2eradication
AT jangjonggeol earlyhydroxychloroquineadministrationforrapidsevereacuterespiratorysyndromecoronavirus2eradication
AT hurjian earlyhydroxychloroquineadministrationforrapidsevereacuterespiratorysyndromecoronavirus2eradication
AT leejongho earlyhydroxychloroquineadministrationforrapidsevereacuterespiratorysyndromecoronavirus2eradication
AT kimhongnam earlyhydroxychloroquineadministrationforrapidsevereacuterespiratorysyndromecoronavirus2eradication
AT leewonhwa earlyhydroxychloroquineadministrationforrapidsevereacuterespiratorysyndromecoronavirus2eradication
AT ahnjunehong earlyhydroxychloroquineadministrationforrapidsevereacuterespiratorysyndromecoronavirus2eradication

Ejemplares similares